These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34043269)

  • 1. State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
    Hampel H; Shaw LM; Aisen P; Chen C; Lleó A; Iwatsubo T; Iwata A; Yamada M; Ikeuchi T; Jia J; Wang H; Teunissen CE; Peskind E; Blennow K; Cummings J; Vergallo A
    Alzheimers Dement; 2022 Jan; 18(1):159-177. PubMed ID: 34043269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.
    Shaw LM; Arias J; Blennow K; Galasko D; Molinuevo JL; Salloway S; Schindler S; Carrillo MC; Hendrix JA; Ross A; Illes J; Ramus C; Fifer S
    Alzheimers Dement; 2018 Nov; 14(11):1505-1521. PubMed ID: 30316776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.
    Carmona-Iragui M; Santos T; Videla S; Fernández S; Benejam B; Videla L; Alcolea D; Blennow K; Blesa R; Lleó A; Fortea J
    J Alzheimers Dis; 2017; 55(4):1489-1496. PubMed ID: 27858714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain.
    Alcolea D; Martínez-Lage P; Izagirre A; Clerigué M; Carmona-Iragui M; Alvarez RM; Fortea J; Balasa M; Morenas-Rodríguez E; Lladó A; Grau O; Blennow K; Lleó A; Molinuevo JL
    J Alzheimers Dis; 2014; 39(4):719-26. PubMed ID: 24254700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary.
    Hampel H; Elhage A; Shaw LM; Aisen P; Chen C; Lleó A; Iwatsubo T; Iwata A; Yamada M; Ikeuchi T; Jia J; Wang H; Teunissen CE; Peskind E; Blennow K; Cummings J; Vergallo A
    Neurodegener Dis Manag; 2022 Oct; 12(5):221-229. PubMed ID: 35866715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Consensus Guidelines on the Application of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: Recommendations of the Irish Network for Biomarkers in Neurodegeneration.
    Miller AM; Begley E; Coen R; Doyle M; Dunne J; Hutchinson S; Kennelly SP; Kenny RA; Killeen RP; Lynch A; O'Dwyer S; O'Neill C; O'Sullvan SS; Rowan MJ; Sheehy N; McGuigan C; Lawlor BA
    Ir Med J; 2016 Dec; 109(10):483. PubMed ID: 28644588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France.
    Cognat E; Mouton Liger F; Troussière AC; Wallon D; Dumurgier J; Magnin E; Duron E; Gabelle A; Croisile B; de la Sayette V; Jager A; Blanc F; Bouaziz-Amar E; Miguet-Alfonsi C; Quillard M; Schraen S; Philippi N; Beaufils E; Pasquier F; Hannequin D; Robert P; Hugon J; Paquet C;
    BMJ Open; 2019 May; 9(5):e026380. PubMed ID: 31152032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research.
    Blazel MM; Lazar KK; Van Hulle CA; Ma Y; Cole A; Spalitta A; Davenport-Sis N; Bendlin BB; Wahoske M; Illingworth C; Gleason CE; Edwards DF; Blazel H; Asthana S; Johnson SC; Carlsson CM
    J Alzheimers Dis; 2020; 77(4):1559-1567. PubMed ID: 32925041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated lumbar punctures within 3 days may affect CSF biomarker levels.
    Olsson M; Ärlig J; Hedner J; Blennow K; Zetterberg H
    Fluids Barriers CNS; 2019 Dec; 16(1):37. PubMed ID: 31831030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.
    Szalárdy L; Zádori D; Klivényi P; Vécsei L
    J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between brain
    Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress update: fluid and imaging biomarkers in Alzheimer's disease.
    Sutphen CL; Fagan AM; Holtzman DM
    Biol Psychiatry; 2014 Apr; 75(7):520-6. PubMed ID: 24012326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Alzheimer's pathology in patients with clinical normal pressure hydrocephalus: correlation of high-volume lumbar puncture results, cortical brain biopsies, and outcomes.
    Pomeraniec IJ; Bond AE; Lopes MB; Jane JA
    J Neurosurg; 2016 Feb; 124(2):382-8. PubMed ID: 26339853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients.
    Boccardi M; Nicolosi V; Festari C; Bianchetti A; Cappa S; Chiasserini D; Falini A; Guerra UP; Nobili F; Padovani A; Sancesario G; Morbelli S; Parnetti L; Tiraboschi P; Muscio C; Perani D; Pizzini FB; Beltramello A; Salvini Porro G; Ciaccio M; Schillaci O; Trabucchi M; Tagliavini F; Frisoni GB
    Eur J Neurol; 2020 Mar; 27(3):475-483. PubMed ID: 31692118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multicenter study on lumbar puncture indication, clinical practice and feasibility].
    Paquet C; Latour F; Saulnier I; Hanon O
    Rev Neurol (Paris); 2012 Jan; 168(1):28-32. PubMed ID: 22153704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment.
    Falgàs N; Tort-Merino A; Balasa M; Borrego-Écija S; Castellví M; Olives J; Bosch B; Férnandez-Villullas G; Antonell A; Augé JM; Lomeña F; Perissinotti A; Bargalló N; Sánchez-Valle R; Lladó A
    Eur J Neurol; 2019 Aug; 26(8):1098-1104. PubMed ID: 30793432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.